Wall Street investors, spurred on by Trump's pro-business agenda, could be ignoring real risks posed by the president.
Akero Therapeutics shares traded near their all-time high as the drugmaker reported positive results in a study of its treatment for liver disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback